In a report issued on March 10, Andrew Berens from Leerink Partners maintained a Buy rating on Theseus Pharmaceuticals (THRX – Research Report), with a price target of $18.00. The company's shares closed last Friday at $9.71, close to its 52-week low of $7.95. According to TipRanks.com, Berens ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.0% and a 40.3% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Currently, the analyst consensus on Theseus Pharmaceuticals is a Moderate Buy with an average price target of $18.00.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-theseus-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Theseus Pharmaceuticals Charts.
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Theseus Pharmaceuticals Charts.